<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00379587</url>
  </required_header>
  <id_info>
    <org_study_id>05-377</org_study_id>
    <nct_id>NCT00379587</nct_id>
  </id_info>
  <brief_title>Rituximab for Prevention of Chronic GVHD</brief_title>
  <official_title>A Phase II Trial of Prophylactic Rituximab Therapy for Prevention of Chronic Graft-vs.-Host Disease After Allogeneic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine if administration of rituximab after allogeneic
      stem cell transplantation can reduce the incidence of chronic GVHD. Chronic GVHD is a medical
      condition that can occur after bone marrow or stem cells are transplanted form one individual
      to another. After the transplant, the donor immune system may recognize the recipient body as
      foreign and may attempt to &quot;reject&quot; the body. Rituximab is a drug that interferes with the
      immune system function by specifically targeting B cells and killing them.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design: The study is designed as a Phase II, open label trial of Rituximab as chronic
      GVHD prophylaxis after HLA-matched, related or unrelated peripheral blood stem cell
      transplantation after ablative or non-ablative conditioning.

      Primary Objective: To determine the incidence of clinically extensive chronic GVHD at one and
      two years after allogeneic stem cell transplantation after a single dose of Rituximab
      administered at 100 days, 6 months, 9 months and 1 year from transplantation as chronic GVHD
      prophylaxis.

      Secondary Objectives: To determine the incidence of adverse hematological events, the
      incidence of infectious complications, the rate of malignant relapse, and the effects on
      donor hematopoietic chimerism after Rituximab administration.

      Eligibility Criteria: Eligible patients will be 18 years of age or greater and will have
      undergone a non-myeloablative or fully ablative transplantation from an HLA-matched (6/6
      loci) or single antigen/allele mismatched (5/6) donor approximately 100 days ago. Adequate
      performance status and organ function will be confirmed prior to enrollment. No ongoing
      infection or acute GVHD will be present at the time of enrollment. Evidence of sustained
      donor chimerism will be confirmed prior to study entry.

      Treatment Description: Chronic GVHD prophylaxis will consist of Rituximab 375 mg/m2
      administered 100 days, 6, 9 and 12 months after transplantation.

      Accrual Objective: 68 patients will be accrued over 12 months.

      Study Duration: Patients will be evaluated for two years after the time of transplantation
      for evaluation of the primary and secondary endpoints. Subjects will be followed
      longitudinally after completion of the study period for determination of clinical status.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Clinician-diagnosed Chronic GVHD at One and Two Years</measure>
    <time_frame>by 1 and 2 years after peripheral blood stem cell (PBSC) infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Grade 3 or Higher Infectious Complications</measure>
    <time_frame>by 1 and 2 years after peripheral blood stem cell (PBSC) infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Relapse or Progression of Disease</measure>
    <time_frame>by 4 years after peripheral blood stem cell (PBSC) infusion</time_frame>
    <description>Percentage of participants with relapsed disease by year 4 post transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Hematological Events</measure>
    <time_frame>by 18 months after peripheral blood stem (PBSC) infusion</time_frame>
    <description>White blood cell decrease, neutrophil cell count decrease, or platelet cell decrease considered possibly or probably related to therapy with rituximab.</description>
  </secondary_outcome>
  <enrollment type="Actual">65</enrollment>
  <condition>Hematological Malignancies</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab at months 3, 6, 9 and 12 post-transplant</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>375 mg/m2 RRituximab</intervention_name>
    <description>Rituximab 375 mg/m2 q3months</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have undergone either ablative or non-myeloablative allogeneic stem cell
             transplantation

          -  Peripheral blood stem cells must have been used as the stem cell source

          -  Patients must have received transplantation from donors who are identical at 6 HLA
             loci, or mismatched at no more than 1 locus.

          -  Patients who have undergone a non-myeloablative stem cell transplant must have &gt; 80%
             donor hematopoiesis within 30 days of study enrollment

          -  18 years of age or older

          -  Performance Status 0-2

          -  Life expectancy of &gt; 100 days

          -  Subjects with CLL are eligible, if there is no more than 20% residual leukemia in the
             bone marrow at the time of study entry

        Exclusion Criteria:

          -  Evidence of relapsed or residual malignancy within 30 days of trial entry

          -  Highly aggressive B cell malignancy, such as Burkitt's lymphoma or Burkitt's-like
             lymphoma

          -  Allogeneic stem cell transplantation using a single or multiple umbilical cord blood
             units or using bone marrow

          -  Evidence of any active uncontrolled infection, or evidence of natural exposure to
             Hepatitis B, Hepatitis C or HIV

          -  Evidence of ongoing gastrointestinal or hepatic acute GVHD, or evidence of greater
             than ongoing Stage I cutaneous acute GVHD

          -  GVHD with chronic features diagnosed prior to day +100 or prior to enrollment

          -  Participation in a clinical trial evaluating another preventative strategy for chronic
             GVHD, or ongoing participation in a clinical trial for therapy of acute GVHD

          -  No Donor Lymphocyte Infusion (DLI) prior to day 100 and not plans for a DLI in the
             upcoming 30 days

          -  Heart failure uncontrolled by medications

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corey Cutler</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2006</study_first_submitted>
  <study_first_submitted_qc>September 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2006</study_first_posted>
  <results_first_submitted>February 3, 2014</results_first_submitted>
  <results_first_submitted_qc>February 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 19, 2014</results_first_posted>
  <last_update_submitted>February 3, 2014</last_update_submitted>
  <last_update_submitted_qc>February 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Corey S. Cutler, MD, MPH</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Rituximab</keyword>
  <keyword>Chronic GVHD</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Rituxan (Rituximab)</title>
          <description>375mg/m^2 IV at 3, 6, 9 and 12 months from transplantation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rituxan (Rituximab)</title>
          <description>375mg/m^2 IV at 3, 6, 9 and 12 months from transplantation</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="65"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" lower_limit="19" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Clinician-diagnosed Chronic GVHD at One and Two Years</title>
        <time_frame>by 1 and 2 years after peripheral blood stem cell (PBSC) infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rituxan (Rituximab)</title>
            <description>375mg/m^2 IV at 3, 6, 9 and 12 months from transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Clinician-diagnosed Chronic GVHD at One and Two Years</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year One</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year Two</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Grade 3 or Higher Infectious Complications</title>
        <time_frame>by 1 and 2 years after peripheral blood stem cell (PBSC) infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rituxan (Rituximab)</title>
            <description>375mg/m^2 IV at 3, 6, 9 and 12 months from transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Grade 3 or Higher Infectious Complications</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year One</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year Two</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Relapse or Progression of Disease</title>
        <description>Percentage of participants with relapsed disease by year 4 post transplant.</description>
        <time_frame>by 4 years after peripheral blood stem cell (PBSC) infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rituxan (Rituximab)</title>
            <description>375mg/m^2 IV at 3, 6, 9 and 12 months from transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Relapse or Progression of Disease</title>
          <description>Percentage of participants with relapsed disease by year 4 post transplant.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adverse Hematological Events</title>
        <description>White blood cell decrease, neutrophil cell count decrease, or platelet cell decrease considered possibly or probably related to therapy with rituximab.</description>
        <time_frame>by 18 months after peripheral blood stem (PBSC) infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rituxan (Rituximab)</title>
            <description>375mg/m^2 IV at 3, 6, 9 and 12 months from transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Hematological Events</title>
          <description>White blood cell decrease, neutrophil cell count decrease, or platelet cell decrease considered possibly or probably related to therapy with rituximab.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Reported Adverse Events (AEs) inlcude events starting on or after day 0 and on or before day 540.</time_frame>
      <desc>If a subject experienced more than 1 of a given AE, the subject is counted only once for that AE. If a subject experienced more than 1 AE in a system organ class (SOC), the subject is counted only once in that SOC.</desc>
      <group_list>
        <group group_id="E1">
          <title>Rituxan (Rituximab)</title>
          <description>375mg/m^2 IV at 3, 6, 9 and 12 months from transplantation</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Interstital Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin Decrease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Neutrophil Decrease</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Platelet Decrease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Alkaline Phosphatase Increase</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Alanine Aminotransferase Increase</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increase</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash/Desquamation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Corey S. Cutler, MD, MPH</name_or_title>
      <organization>Dana-Farber Cancer Institute</organization>
      <phone>617-632-5946</phone>
      <email>corey_cutler@dfci.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

